E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Novo Nordisk’s Awiqli offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to one.
imphoenix82
Novo Nordisk has licensed HRS-1596, a Phase 1-ready oral GLP-1/GIP dual agonist from Hengrui Pharma, in a deal worth up to $2.6 billion, while new real-world data linked semaglutide 2 mg with a lower risk of major adverse cardiovascular events than switching to tirzepatide
imphoenix82
Under the rebrand, ‘Novo’ will be used as the company’s day-to-day name, while Novo Nordisk A/S will remain its legal global company name.
imphoenix82
Novo Nordisk and AWS have created a co-innovation hub in London, where engineers and scientists from both companies work together to accelerate drug discovery and development.
imphoenix82
The court found that Ceban infringed Novo Nordisk’s supplementary protection certificate covering semaglutide and ordered it to cease the infringing activities.
imphoenix82
Novo Nordisk alleges Lilly’s advertisements for Zepbound and Mounjaro mislead consumers by comparing the drugs with lower-dose versions of Wegovy and Ozempic.
imphoenix82
Eligible Medicare beneficiaries can now access Wegovy in both injection and oral forms for a monthly copayment of $50 through the programme, which will remain in place until the end of 2027.
imphoenix82
Novo Nordisk plans to begin a phase 3 development programme for zenagamtide in adults with type 2 diabetes during the second half of 2026.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
